Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 391 first isolates · MED-B · Febrile UTI / pyelonephritis · 2023-11-19 → 2024-11-17
Internal medicine BNarrowest option reaching 80 % coverage, no active warning
meropenem 86 % (82 %–89 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (9 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
Most likely organisms for this profile
Escherichia coli
55 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Klebsiella oxytoca
5 %
Pseudomonas aeruginosa
5 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.